menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Bayer acquires rights in Puhe BioPharma cancer drug candidate

    REUTERS

    Bayer Presents New Heart Failure Data in ACC.25

    BUSINESSWIRE

    400+ Studies Reviewed Over 30 Years

    BUSINESSWIRE

    Bayer hit with $2 B Roundup verdict in Georgia cancer case

    REUTERS

    Bayer Seeks Investor Nod For 35% Cash Call To Cover Litigation

    REUTERS

    Late-Breaking QUANTI CNS Data Presented At ECR 2025

    BUSINESSWIRE

    Bayer Aspirin Promotes Heart Health With “See Their Risks” Campaign

    BUSINESSWIRE

    Bayer files for approval of finerenone in heart failure in Japan

    INDPHARMAPOST

    Nubeqa Data Reinforce Safety & Efficacy In Prostate Cancer

    BUSINESSWIRE

    Bayer Presents Prostate Cancer Data At 2025 ASCO GU Symposium

    BUSINESSWIRE

    Bayer Launches Survey On Global Attitudes Toward Technologies

    BUSINESSWIRE

    Bayer’s pharma growth strategy progressing well as pipeline

    INDPHARMAPOST

    Bayer’s Pharma Growth Strategy Advances With Pipeline Progress

    BUSINESSWIRE

    Bayer moves allogeneic cell therapy into Ph 3 Parkinson`s trial

    FIERCE BIOTECH

    Bayer’s hot flash drug hits goal in phase 3 breast cancer trial

    PRESS RELEASE

    Orion’s partner Bayer in China for 3rd indication of darolutamide

    PRESS RELEASE

    Regeneron to expand high-dose Eylea`s label after Ph 3 win

    BIOSPACE

    Bayer opens Berlin incubator and welcomes first resident

    PHARMAPHORUM

    FDA Accepts NDA in Metastatic Hormone-Sensitive Prostate Cancer

    BUSINESSWIRE

    Bayer acquires rights to Cytokinetics` heart drug in Japan

    REUTERS

    Bayer shareholders call on CEO to stem the tide of bad news

    REUTERS

    Bayer CEO Admits Earnings ‘Not Pretty,’ Urges Investor Calm

    BIOSPACE

    Bayer`s `transition year` looms as Xarelto sales falter

    FIERCE PHARMA

    D.E. Shaw Takes $108M Short Bet on Bayer, Filing Shows

    REUTERS

    Bayer cuts FY operating profit outlook on weak agriculture markets

    REUTERS

    Bayer & Liveo Launch Eco-Friendly Blister Packaging

    BUSINESSWIRE

    Bayer and Dewpoint sign Licensing Agreement for Heart Disease Program

    GLOBENEWSWIRE

    Eylea 8 mg Efficacy In Diabetic Macular Edema Confirmed At 3 Years

    INDPHARMAPOST

    Bayer submits EU marketing application for menopause relief drug

    REUTERS

    Orion`s Partner Bayer Submits Application For Darolutamide

    GLOBENEWSWIRE

    Bayer applies for third indication of Nubeqa in EU

    REUTERS

    Bayer must pay $78 million in latest Roundup cancer trial, jury finds

    REUTERS

    US judicial panel to examine litigation finance disclosure

    REUTERS

    FDA Accepts New Drug Application For Elinzanetant

    BUSINESSWIRE

    Bayer And MOMA Therapeutics Enter Oncology Collaboration

    BUSINESSWIRE

    Orion`s Partner Bayer Submits Application For Darolutamide

    GLOBENEWSWIRE

    Bayer Submits sNDA For NUBEQA In Prostate Cancer

    BUSINESSWIRE

    New Study Evaluates Awareness Of High Breast Density Risk

    BUSINESSWIRE

    Bayer buses women for mammograms in rural breast health push

    FIERCE PHARMA

    Bayer, UPMC, and PA Senate Collaborate on Breast Health Awareness

    BUSINESSWIRE

    Nubeqa Reduces Progression Risk In Prostate Cancer Trial

    BUSINESSWIRE

    Bayer, others defeat US farmers` chemical price-fixing lawsuit

    REUTERS

    Bayer hopes to expand Nubeqa`s prostate cancer reach with chemo-free regimen

    FIERCE PHARMA

    Bayer Consumer Health Hosts Bayer 04 Leverkusen U.S. Trophy Tour

    BUSINESSWIRE

    Jury rules in favor of Bayer`s Monsanto in Philadelphia trial over Roundup

    REUTERS

    PanTera Attracts $102.5M In Series A For Radiopharmaceutical Manufacturing

    ENDPTS

    Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

    BIOSPACE

    OASIS 3 Data Support Elinzanetant For Menopausal Symptoms

    BUSINESSWIRE

    BAY 2927088 Results For HER2-Mutant NSCLC At WCLC

    BUSINESSWIRE

    Bayer To Present New Prostate Cancer Data At ESMO 2024

    BUSINESSWIRE

    Bayer to Unveil New Data From Phase III OASIS 3 Study on Elinzanetant

    BUSINESSWIRE

    Bayer builds entire ‘ecosystem’ around One A Day cell health support supplement

    FIERCE PHARMA

    Bayer`s asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes

    FIERCE BIOTECH

    Bayer`s Kerendia Reduces Cardio Death Risk By 16% In Heart Failure Patients

    FIERCE PHARMA

    Bayer starts Phase III Trial in Non-Small Cell Lung Cancer (NSCLC)

    BUSINESSWIRE

    ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data

    BUSINESSWIRE

    Bayer pens $547M biobucks pact with biotech pushing the noncoding RNA

    PRESS RELEASE

    Bayer Advances In Heart Failure Management With FINEARTS-HF Study Data

    PHARMABIZ

    Bayer layoffs hit Switzerland with 150 cuts at Basel consumer health hub

    FIERCE PHARMA

    JAMA Publishes Elinzanetant Phase III Data

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.